Patient App to Ease Anxiety Enters Testing in Pivotal Phase of Study

FDA Orphan Drug Designation Awarded to Ifenprodil for IPF

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ifenprodil, the active agent in NP-120, an investigational oral medicine for idiopathic pulmonary fibrosis (IPF). This designation gives Algernon Pharmaceuticals, as the therapy’s developer, certain incentives including tax credits, fee waivers, and a guarantee for…

Study Testing App to Ease Anxiety Opens Nationwide Enrollment

The first-of-its-kind Vicore COMPANION Study is now recruiting participants across the U.S. to test Almee, a new artificial intelligence (AI) app designed to help people with pulmonary fibrosis (PF) manage their anxiety. Developed by Vicore Pharma, Almee is an investigational digital cognitive behavioral therapy (CBT) that uses…

With Each November, I Celebrate 3 Lives That Have Passed

The holiday season is upon us! Here in the United States, Thanksgiving was last week, and the Macy’s Thanksgiving Day Parade heralded the arrival of Santa Claus. But November, for the past two years, has been a month of loss for me. COVID-19 and transplant In March 2020, the reality…

Kinarus Explores Partnership in China to Support Its Phase 2 Trials

Kinarus Therapeutics and the Great Health Companion Group (GHCG) in China are exploring a partnership to fund further development of KIN001, Kinarus’ potential treatment for idiopathic pulmonary fibrosis (IPF). Switzerland-based Kinarus and GHCG, a subsidiary of global China conglomerate Hakim Unique Group, are also looking into ways to…

Deciding Whether to Have Kids Can Be Complicated With IPF

Being diagnosed with a chronic illness changes everything. In addition to the physical changes, patients endure emotional, mental, and social ones as well. This is especially true for those of us thrown into the chronic illness world as a young adult, when our brains have just finished developing but our…